Skip to main content

Table 2 Disease activity, HAQ score and laboratory parameters of inflammation during the study

From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

  M0 (N = 107) M1 (N = 106) M3 (N = 104) M6 (N = 97) M12 (N = 77) P*, M0 vs M6 (N = 97) P*, M0 vs M12 (N = 77) P#
DAS28-ESR 4.93 ± 1.3 3.55 ± 1.2 2.8 ± 1.2 2.5 ± 1.2 2.3 ± 1.3 <  10−4 <  10−4 <  10−4
HAQ 1.4 ± 0.6 Not evaluated Not evaluated 0.97 ± 0.6 0.98 ± 0.6 <  10−4 <  10−4 <  10−4
ESR (mm/h) 27.8 ± 22.8 8.2 ± 8.4 6.5 ± 10.2 6.1 ± 7.1 5.8 ± 1.8 <  10−4 <  10−4 <  10−4
CRP (mg/L) 17.7 ± 26.7 5.4 ± 15.4 4.7 ± 12.8 2.4 ± 4.4 2.3 ± 4.5 <  10−4 <  10−4 <  10−4
IL-6 (pg/mL) 26.4 ± 37.8 72.3 ± 76 62.3 ± 78.7 53.1 ± 58.7 53.8 ± 110 <  10−4 0.04 0.04
  1. Results are given as mean ± SD
  2. M month, HAQ health assessment questionnaire, ESR eythrocyte sedimentation rate, CRP C-reactive protein
  3. *Paired Student’s t test
  4. #Sensitivity analysis
\